FDA AI in neurology is a fragmented but important category spanning stroke imaging workflows, seizure monitoring, EEG review, sleep neuro, brain injury assessment, and navigation tools.
Cardiology is becoming one of the clearest bridges between regulated medical AI, remote monitoring, ECG analysis, and consumer heart devices.
Radiology dominates the FDA AI-enabled medical device list because medical imaging already turns the body into structured data, making it the first large proving ground for regulated medical AI.
The FDA’s list of AI-enabled medical devices reveals a quieter medical AI revolution: narrow, regulated tools already helping clinicians see, measure, monitor, and act earlier.
A UC Berkeley and City of Hope team published a landmark AI platform called MechanoAge in Lancet’s eBioMedicine that measures the physical stress-response of individual breast cells to identify cancer…
A Nobel laureate on its board. The world’s largest pharmaceutical company as a founding partner. And a scientific mission to build drugs that target aging itself. Inside Insilico Medicine’s Longevity…
Insilico Medicine has formed the industry’s first Longevity Board, chaired by Eli Lilly’s Group VP of Molecular Discovery and featuring Nobel laureate Michael Levitt. Inside the AI strategy, dual-purpose targets,…
For the first time in pharmaceutical history, molecules designed almost entirely by artificial intelligence are surviving Phase 2 trials in real patients. From Insilico’s rentosertib to Isomorphic Labs’ multi-billion dollar…
Researchers at the University of Geneva used machine learning to map gut bacteria at the subspecies level and detect 90% of colorectal cancers from a simple stool sample. The test…
More than 173 AI-discovered drug programs are now in clinical development, with the first Phase III readouts arriving this year. From Insilico Medicine’s rentosertib to Generate Biomedicines’ AI-designed antibody for…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.